

# Investors

*On March 26, 2009, Genentech, Inc. became a wholly-owned member of the Roche Group. In connection with the privatization, public shareholders received \$95.00 per share for their shares and Genentech's common stock (symbol: DNA) ceased trading on the New York Stock Exchange.*

## Genentech Historical Prices

[NYSE: GNE, 1988 - June 15, 1999 \(182K/PDF\)](#)

[NYSE: DNA, July 20, 1999 - March 26, 2009 \(169K/PDF\)](#)

## Share tendering

**Questions regarding Genentech shares not tendered in the privatization transaction should be directed to BNY Mellon Shareowner Services by phone:**

+1 866-223-9154 from within the United States, Canada or Puerto Rico (toll free)  
+1 201-680-6579 from outside the United States

Phones are open 9am to 6pm New York time, Monday through Friday, except for bank holidays.

## Transmittal materials

### **By Mail:**

BNY Mellon Shareowner Services  
Attn: Corporate Action Dept.  
PO Box 358300  
Pittsburgh, PA 15252-8300

## By Overnight Courier or By Hand:

### **BNY Mellon Shareowner Services**

Attn: Corporate Action Dept., 27th Floor  
480 Washington Boulevard  
Jersey City, NJ 07310

## **More information**

Roche Investor Relations North America  
Information for U.S. Investors